cancer malignancy
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Patient with melanoma, NSCLC or urogenital cancers >= 2 years since treatment with at least one cycle of immune checkpoint inhibitor (CTLA-4 inhibitor, PD-(L)1 inhibitor, or both) within the Department of Medical Oncology or Pulmonary Oncology of the UMCG. 2. Age >=18 years at time of immune checkpoint inhibitor treatment 3. Understand or abide to the study procedures 4. Have given informed consent A caregiver must meet all of the following criteria: 1. Age >=18 years 2. Understand or abide to the study procedures 3. Have given informed consent
Exclusion criteria
Exclusion criteria: 1. As previous or subsequent therapies, only surgery and palliative radiotherapy is allowed (excluding radiotherapy in the head-neck and brain region) 2. Previous treatment in the past ten years for malignancy other than melanoma (excluding non-melanoma skin cancer, cervical intra-epithelial neoplasia (CIN) or carcinoma in situ of breast) (for patients: other than current malignancy) 3. History of ear-nose-throat disease or auto-immune disorder affecting taste, smell, mouth mucosa, or saliva production (for patients: before start ICI)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Taste and smell dysfunction, measured using taste strips and Sniffin* Sticks. | — |
Secondary
| Measure | Time frame |
|---|---|
| Salivary flow rate, salivary pH. proteins and electrolytes, xerostomia, and perceived taste and smell dysfunction and impact of taste and smell dysfunction. | — |
Countries
Netherlands
Outcome results
None listed